At a glance
- Originator Novartis
- Class Small molecules
- Mechanism of Action Potassium channel agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 14 Sep 2006 Discontinued - Phase-II for Asthma (unspecified route)
- 22 Sep 2003 Phase-II clinical trials in Asthma (unspecified route)
- 19 Jul 2002 Clinical trials in Asthma (unspecified route)